ErVimmune

Startup Plus

ErVimmune develops cancer vaccines and T cell-based therapies as breakthrough immunotherapies to address unmet medical needs in cold tumors.

We are dedicated to discovering more accurate non-mutated tumor epitopes that are shared across patients and indications. Supported by a proprietary, AI-driven target discovery platform, we focus on non-conventional antigens derived from human endogenous retroviruses (HERVs) as targets that we validate by proteomics and immunology assays. From bioinformatics to proteomics!

website